These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8413427)

  • 1. Antiemetic effects of ondansetron and metopimazine.
    Roila F; Ballatori E; Del Favero A
    N Engl J Med; 1993 Oct; 329(18):1356-7. PubMed ID: 8413427
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis.
    Khamales S; Bethune-Volters A; Chidiac J; Bensaoula O; Delgado A; Di Palma M
    Anticancer Drugs; 2006 Feb; 17(2):217-24. PubMed ID: 16428941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy.
    Sigsgaard T; Herrstedt J; Handberg J; Kjaer M; Dombernowsky P
    J Clin Oncol; 2001 Apr; 19(7):2091-7. PubMed ID: 11283143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
    Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
    Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.
    Herrstedt J; Sigsgaard T; Handberg J; Schousboe BM; Hansen M; Dombernowsky P
    J Clin Oncol; 1997 Apr; 15(4):1690-6. PubMed ID: 9193370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J; Sigsgaard T; Boesgaard M; Jensen TP; Dombernowsky P
    N Engl J Med; 1993 Apr; 328(15):1076-80. PubMed ID: 8455664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design.
    Nathan PC; Tomlinson G; Dupuis LL; Greenberg ML; Ota S; Bartels U; Feldman BM
    Support Care Cancer; 2006 Mar; 14(3):268-76. PubMed ID: 16052316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled studies of metopimazine for the treatment of nausea and vomiting.
    Moertel CG; Reitemeier RJ
    J Clin Pharmacol; 1973 Jul; 13(7):283-7. PubMed ID: 4576417
    [No Abstract]   [Full Text] [Related]  

  • 9. Fighting nausea in the '90s: more and better anti-emetics can help.
    Saphir A
    J Natl Cancer Inst; 1997 Sep; 89(17):1252-5. PubMed ID: 9293911
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antiemetic effect of metopimazine measured by the apomorphine test].
    Cournot A; Berlin I; Caspi M
    Therapie; 1987; 42(2):183-6. PubMed ID: 3616994
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine.
    Herrstedt J
    Dan Med Bull; 1998 Sep; 45(4):412-22. PubMed ID: 9777292
    [No Abstract]   [Full Text] [Related]  

  • 12. Ondansetron compared with metoclopramide in the treatment of PONV.
    Harper CM; Barker JP
    Br J Anaesth; 1998 Mar; 80(3):407-8. PubMed ID: 9623448
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.
    Ellebaek E; Herrstedt J
    Curr Opin Support Palliat Care; 2008 Mar; 2(1):28-34. PubMed ID: 18685391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nurses' perceptions of antiemetic effectiveness.
    Rhodes VA; McDaniel RW; Simms SG; Johnson M
    Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ondansetron in nausea and vomiting induced by spinal morphine.
    Mercadante S; Sapio M; Serretta R
    J Pain Symptom Manage; 1998 Oct; 16(4):259-62. PubMed ID: 9803054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ondansetron as an effective antiemetic in the rural, out-of-hospital setting.
    Benner JP; Ferguson JD; Judkins AE; O'Connor RE; Brady WJ
    Am J Emerg Med; 2011 Sep; 29(7):818-21. PubMed ID: 21641151
    [No Abstract]   [Full Text] [Related]  

  • 17. Ondansetron: perioperative use of a serotonin receptor antagonist for the prevention and treatment of nausea and vomiting.
    Early TE; Charbonneau J; McKnight G; Jenkins P
    J Post Anesth Nurs; 1995 Dec; 10(6):320-3. PubMed ID: 8632370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiemetic therapy for nausea and vomiting in the emergency department.
    Patanwala AE; Amini R; Hays DP; Rosen P
    J Emerg Med; 2010 Sep; 39(3):330-6. PubMed ID: 20022195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neither ondansetron nor metoclopramide reduced nausea and vomiting in the emergency department.
    Pitts SR
    Ann Intern Med; 2014 Dec; 161(12):JC3. PubMed ID: 25506875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.